Chemists across India plan a nationwide strike on May 20 [2] to protest the business practices of online pharmacy platforms.
The action threatens to disrupt the distribution of essential medications across the country, forcing government health agencies to create contingency plans to prevent a public health crisis.
Organized by the All India Organisation of Chemists and Druggists (AIOCD), the protest is driven by allegations of unfair pricing and aggressive business strategies used by e-pharma companies [1]. Approximately 1.2 million chemists are expected to participate in the strike [1].
In response to the potential shortage of medicine, the Maharashtra Food and Drug Administration (FDA) has taken preventative measures in Mumbai [2]. The agency said it has set up emergency control rooms throughout the city to monitor the supply of critical drugs, and ensure that patients can still access necessary treatments [2].
Local chemists argue that the rise of digital pharmacy platforms has created an uneven playing field. They said the pricing models used by these companies undermine traditional brick-and-mortar pharmacies, which serve as the primary point of care for millions of citizens.
The FDA's strategy in Mumbai focuses on maintaining a steady flow of life-saving medicines during the period of unrest. Officials said the control rooms will serve as hubs to redirect supply and manage emergency requests from hospitals and clinics [2].
While the strike is nationwide, the concentration of pharmaceutical distribution in hubs like Mumbai makes the city a critical focal point for the FDA's emergency response. The AIOCD said the protest will continue until the government addresses the grievances regarding the digital pharmacy sector [1].
“1.2 million chemists are expected to participate in the strike”
This conflict highlights the growing tension between traditional healthcare retail and the rapid digitalization of pharmaceutical sales in India. The scale of the protest suggests a systemic instability in how medicine is priced and distributed, indicating that regulatory frameworks have not kept pace with the growth of e-pharma platforms.
